The C- part of the cases focuses on the actions GSK had to take being pressured by the NGOs. The company had been defeated and it agreed to several licensing agreements and price reductions, but the NGOs are still not satisfied. The topic was also gaining importance in the Western media and the big question now was whether it was starting to become an issue in more developed countries, where the vast majority of GSKs’ sales and profits were being made.
GlaxoSmithKline, Health Care, Pharmaceuticals
2001 - 2004
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
Research Information & Knowledge Hub for additional information on IMD publications